Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Character of Immune Disturbances and Their Correction by Including the Interferon Inductor in Complex Therapy for Turboperitoneal Infertility Associated with Chlamydial Infection.

Russian journal of immunology : RJI : official journal of Russian Society of Immunology

Uzlova TV, Teplova SN, Medvedev BI.
PMID: 12687123
Russ J Immunol. 1999 Jul;4(2):159-164.

The character of immune disturbances was studied in women with tuboperitoneal infertility associated with a chlamydial infection. The immunological methods included a study of the population and subpopulation composition of peripheral blood lymphocytes (CD3, CD7, CD22, CD4, CD8, ratio...

Cite
Uzlova TV, Teplova SN, Medvedev BI. Character of Immune Disturbances and Their Correction by Including the Interferon Inductor in Complex Therapy for Turboperitoneal Infertility Associated with Chlamydial Infection. Russ J Immunol. 1999;4(2):159-164
Uzlova, T. V., Teplova, S. N., & Medvedev, B. I. (1999). Character of Immune Disturbances and Their Correction by Including the Interferon Inductor in Complex Therapy for Turboperitoneal Infertility Associated with Chlamydial Infection. Russian journal of immunology : RJI : official journal of Russian Society of Immunology, 4(2), 159-164.
Uzlova, Tatyana V., et al. "Character of Immune Disturbances and Their Correction by Including the Interferon Inductor in Complex Therapy for Turboperitoneal Infertility Associated with Chlamydial Infection." Russian journal of immunology : RJI : official journal of Russian Society of Immunology vol. 4,2 (1999): 159-164.
Uzlova TV, Teplova SN, Medvedev BI. Character of Immune Disturbances and Their Correction by Including the Interferon Inductor in Complex Therapy for Turboperitoneal Infertility Associated with Chlamydial Infection. Russ J Immunol. 1999 Jul;4(2):159-164. PMID: 12687123.
Copy Download .nbib Format: NLM
C1 Complex: An Adaptable Proteolytic Module for Complement and Non-Complement Functions.

Frontiers in immunology

Lu J, Kishore U.
PMID: 28596769
Front Immunol. 2017 May 24;8:592. doi: 10.3389/fimmu.2017.00592. eCollection 2017.

Complement C1 is the defining component of the classical pathway. Within the C1qC1r

Cite
Lu J, Kishore U. C1 Complex: An Adaptable Proteolytic Module for Complement and Non-Complement Functions. Front Immunol. 2017;8:592doi: 10.3389/fimmu.2017.00592.
Lu, J., & Kishore, U. (2017). C1 Complex: An Adaptable Proteolytic Module for Complement and Non-Complement Functions. Frontiers in immunology, 8592. https://doi.org/10.3389/fimmu.2017.00592
Lu, Jinhua, and Kishore, Uday. "C1 Complex: An Adaptable Proteolytic Module for Complement and Non-Complement Functions." Frontiers in immunology vol. 8 (2017): 592. doi: https://doi.org/10.3389/fimmu.2017.00592
Lu J, Kishore U. C1 Complex: An Adaptable Proteolytic Module for Complement and Non-Complement Functions. Front Immunol. 2017 May 24;8:592. doi: 10.3389/fimmu.2017.00592. eCollection 2017. PMID: 28596769; PMCID: PMC5442170.
Copy Download .nbib Format: NLM
Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma.

Proteomics. Clinical applications

Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Willé DR, Wu W, Yates JW, Gloger IS.
PMID: 21136851
Proteomics Clin Appl. 2008 Apr;2(4):467-77. doi: 10.1002/prca.200780101. Epub 2008 Mar 07.

Emerging disease modifying therapeutic strategies for Alzheimer's disease (AD) have generated a critical need for biomarkers of early stage disease. Here, we describe the identification and assessment of a number of candidate biomarkers in patients with mild to moderate...

Cite
Cutler P, Akuffo EL, Bodnar WM, et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin Appl. 2008;2(4):467-77doi: 10.1002/prca.200780101.
Cutler, P., Akuffo, E. L., Bodnar, W. M., Briggs, D. M., Davis, J. B., Debouck, C. M., Fox, S. M., Gibson, R. A., Gormley, D. A., Holbrook, J. D., Hunter, A. J., Kinsey, E. E., Prinjha, R., Richardson, J. C., Roses, A. D., Smith, M. A., Tsokanas, N., Willé, D. R., Wu, W., Yates, J. W., & Gloger, I. S. (2008). Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics. Clinical applications, 2(4), 467-77. https://doi.org/10.1002/prca.200780101
Cutler, Paul, et al. "Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma." Proteomics. Clinical applications vol. 2,4 (2008): 467-77. doi: https://doi.org/10.1002/prca.200780101
Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Willé DR, Wu W, Yates JW, Gloger IS. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin Appl. 2008 Apr;2(4):467-77. doi: 10.1002/prca.200780101. Epub 2008 Mar 07. PMID: 21136851.
Copy Download .nbib Format: NLM
Complement, c1q, and c1q-related molecules regulate macrophage polarization.

Frontiers in immunology

Bohlson SS, O'Conner SD, Hulsebus HJ, Ho MM, Fraser DA.
PMID: 25191325
Front Immunol. 2014 Aug 21;5:402. doi: 10.3389/fimmu.2014.00402. eCollection 2014.

Complement is a critical system of enzymes, regulatory proteins, and receptors that regulates both innate and adaptive immune responses. Natural mutations in complement molecules highlight their requirement in regulation of a variety of human conditions including infectious disease and...

Cite
Bohlson SS, O'Conner SD, Hulsebus HJ, et al. Complement, c1q, and c1q-related molecules regulate macrophage polarization. Front Immunol. 2014;5:402doi: 10.3389/fimmu.2014.00402.
Bohlson, S. S., O'Conner, S. D., Hulsebus, H. J., Ho, M. M., & Fraser, D. A. (2014). Complement, c1q, and c1q-related molecules regulate macrophage polarization. Frontiers in immunology, 5402. https://doi.org/10.3389/fimmu.2014.00402
Bohlson, Suzanne S, et al. "Complement, c1q, and c1q-related molecules regulate macrophage polarization." Frontiers in immunology vol. 5 (2014): 402. doi: https://doi.org/10.3389/fimmu.2014.00402
Bohlson SS, O'Conner SD, Hulsebus HJ, Ho MM, Fraser DA. Complement, c1q, and c1q-related molecules regulate macrophage polarization. Front Immunol. 2014 Aug 21;5:402. doi: 10.3389/fimmu.2014.00402. eCollection 2014. PMID: 25191325; PMCID: PMC4139736.
Copy Download .nbib Format: NLM
Serum Complement C1q Activity Is Associated With Obstructive Coronary Artery Disease.

Frontiers in cardiovascular medicine

Guo S, Mao X, Li X, Ouyang H, Gao Y, Ming L.
PMID: 33996933
Front Cardiovasc Med. 2021 Apr 29;8:618173. doi: 10.3389/fcvm.2021.618173. eCollection 2021.

No abstract available.

Cite
Guo S, Mao X, Li X, et al. Serum Complement C1q Activity Is Associated With Obstructive Coronary Artery Disease. Front Cardiovasc Med. 2021;8:618173doi: 10.3389/fcvm.2021.618173.
Guo, S., Mao, X., Li, X., Ouyang, H., Gao, Y., & Ming, L. (2021). Serum Complement C1q Activity Is Associated With Obstructive Coronary Artery Disease. Frontiers in cardiovascular medicine, 8618173. https://doi.org/10.3389/fcvm.2021.618173
Guo, Shuren, et al. "Serum Complement C1q Activity Is Associated With Obstructive Coronary Artery Disease." Frontiers in cardiovascular medicine vol. 8 (2021): 618173. doi: https://doi.org/10.3389/fcvm.2021.618173
Guo S, Mao X, Li X, Ouyang H, Gao Y, Ming L. Serum Complement C1q Activity Is Associated With Obstructive Coronary Artery Disease. Front Cardiovasc Med. 2021 Apr 29;8:618173. doi: 10.3389/fcvm.2021.618173. eCollection 2021. PMID: 33996933; PMCID: PMC8116493.
Copy Download .nbib Format: NLM
The activation of complement C1q and C3 in glomeruli may accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology.

Journal of diabetes investigation

Jiao Y, Jiang S, Wang Y, Yu T, Zou G, Zhuo L, Li W.
PMID: 34932275
J Diabetes Investig. 2021 Dec 21; doi: 10.1111/jdi.13739. Epub 2021 Dec 21.

AIMS/INTRODUCTION: It is not unclear whether the complement system is involved in the pathogenesis of diabetic nephropathy (DN). We explored the role of the complement system in glomeruli from patients with DN using integrated transcriptomic bioinformatics analysis and renal...

Cite
Jiao Y, Jiang S, Wang Y, et al. The activation of complement C1q and C3 in glomeruli may accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology. J Diabetes Investig. 2021;doi: 10.1111/jdi.13739.
Jiao, Y., Jiang, S., Wang, Y., Yu, T., Zou, G., Zhuo, L., & Li, W. (2021). The activation of complement C1q and C3 in glomeruli may accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology. Journal of diabetes investigation, . https://doi.org/10.1111/jdi.13739
Jiao, Yuanyuan, et al. "The activation of complement C1q and C3 in glomeruli may accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology." Journal of diabetes investigation vol. (2021). doi: https://doi.org/10.1111/jdi.13739
Jiao Y, Jiang S, Wang Y, Yu T, Zou G, Zhuo L, Li W. The activation of complement C1q and C3 in glomeruli may accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology. J Diabetes Investig. 2021 Dec 21; doi: 10.1111/jdi.13739. Epub 2021 Dec 21. PMID: 34932275.
Copy Download .nbib Format: NLM
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.

Cancer immunology research

Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT.
PMID: 34039653
Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26.

The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement...

Cite
Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021;9(8):891-908doi: 10.1158/2326-6066.CIR-20-0532.
Daugan, M. V., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., Poillerat, V., Grunenwald, A., Lacroix, G., Bougouin, A., Meylan, M., Verkarre, V., Oudard, S. M., Mejean, A., Vano, Y. A., Perkins, G., Validire, P., Cathelineau, X., Sanchez-Salas, R., Damotte, D., Fremeaux-Bacchi, V., Cremer, I., Sautès-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2021). Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer immunology research, 9(8), 891-908. https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan, Marie V, et al. "Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s." Cancer immunology research vol. 9,8 (2021): 891-908. doi: https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. PMID: 34039653.
Copy Download .nbib Format: NLM
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.

Cancer immunology research

Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT.
PMID: 34039653
Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26.

The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement...

Cite
Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021;9(8):891-908doi: 10.1158/2326-6066.CIR-20-0532.
Daugan, M. V., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., Poillerat, V., Grunenwald, A., Lacroix, G., Bougouin, A., Meylan, M., Verkarre, V., Oudard, S. M., Mejean, A., Vano, Y. A., Perkins, G., Validire, P., Cathelineau, X., Sanchez-Salas, R., Damotte, D., Fremeaux-Bacchi, V., Cremer, I., Sautès-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2021). Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer immunology research, 9(8), 891-908. https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan, Marie V, et al. "Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s." Cancer immunology research vol. 9,8 (2021): 891-908. doi: https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. PMID: 34039653.
Copy Download .nbib Format: NLM
Comparative analysis of serum proteomes of moyamoya disease and normal controls.

Journal of Korean Neurosurgical Society

Koh EJ, Kim HN, Ma TZ, Choi HY, Kwak YG.
PMID: 20717506
J Korean Neurosurg Soc. 2010 Jul;48(1):8-13. doi: 10.3340/jkns.2010.48.1.8. Epub 2010 Jul 31.

OBJECTIVE: The etiology and pathogenesis of moyamoya disease remain unclear. Furthermore, the definitive diagnostic protein-biomarkers for moyamoya disease are still unknown. The present study analyzed serum proteomes from normal controls and moyamoya patients to identify novel serological biomarkers for...

Cite
Koh EJ, Kim HN, Ma TZ, et al. Comparative analysis of serum proteomes of moyamoya disease and normal controls. J Korean Neurosurg Soc. 2010;48(1):8-13doi: 10.3340/jkns.2010.48.1.8.
Koh, E. J., Kim, H. N., Ma, T. Z., Choi, H. Y., & Kwak, Y. G. (2010). Comparative analysis of serum proteomes of moyamoya disease and normal controls. Journal of Korean Neurosurgical Society, 48(1), 8-13. https://doi.org/10.3340/jkns.2010.48.1.8
Koh, Eun-Jeong, et al. "Comparative analysis of serum proteomes of moyamoya disease and normal controls." Journal of Korean Neurosurgical Society vol. 48,1 (2010): 8-13. doi: https://doi.org/10.3340/jkns.2010.48.1.8
Koh EJ, Kim HN, Ma TZ, Choi HY, Kwak YG. Comparative analysis of serum proteomes of moyamoya disease and normal controls. J Korean Neurosurg Soc. 2010 Jul;48(1):8-13. doi: 10.3340/jkns.2010.48.1.8. Epub 2010 Jul 31. PMID: 20717506; PMCID: PMC2916155.
Copy Download .nbib Format: NLM
Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin.

International journal of peptides

Hair PS, Cunnion KM, Krishna NK.
PMID: 29081812
Int J Pept. 2017;2017:9454583. doi: 10.1155/2017/9454583. Epub 2017 Sep 10.

Hemoglobin is the natural carrier of oxygen in red blood cells (RBCs). While intracellular hemoglobin provides life-sustaining oxygen transport, extracellular free hemoglobin displays toxicity due to inherent peroxidase activity generating reactive oxygen species that subsequently react with the hemoglobin...

Cite
Hair PS, Cunnion KM, Krishna NK. Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin. Int J Pept. 2017;2017:9454583doi: 10.1155/2017/9454583.
Hair, P. S., Cunnion, K. M., & Krishna, N. K. (2017). Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin. International journal of peptides, 20179454583. https://doi.org/10.1155/2017/9454583
Hair, Pamela S, et al. "Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin." International journal of peptides vol. 2017 (2017): 9454583. doi: https://doi.org/10.1155/2017/9454583
Hair PS, Cunnion KM, Krishna NK. Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin. Int J Pept. 2017;2017:9454583. doi: 10.1155/2017/9454583. Epub 2017 Sep 10. PMID: 29081812; PMCID: PMC5610871.
Copy Download .nbib Format: NLM
Effect of complement C1-esterase inhibitor on brain edema and inflammation after mild traumatic brain injury in an animal model.

Clinical and experimental emergency medicine

Weiss E, Dhir T, Collett A, Reola M, Kaplan M, Minimo C, Omert L, Leung P.
PMID: 32635699
Clin Exp Emerg Med. 2020 Jun;7(2):87-94. doi: 10.15441/ceem.19.050. Epub 2020 Jun 30.

OBJECTIVE: Traumatic brain injury (TBI) is characterized by damage to the blood-brain barrier, inflammation, and edema formation. In this pilot study, we aimed to investigate the effects of a complement inhibitor, C1-esterase inhibitor (C1 INH), on brain edema and...

Cite
Weiss E, Dhir T, Collett A, et al. Effect of complement C1-esterase inhibitor on brain edema and inflammation after mild traumatic brain injury in an animal model. Clin Exp Emerg Med. 2020;7(2):87-94doi: 10.15441/ceem.19.050.
Weiss, E., Dhir, T., Collett, A., Reola, M., Kaplan, M., Minimo, C., Omert, L., & Leung, P. (2020). Effect of complement C1-esterase inhibitor on brain edema and inflammation after mild traumatic brain injury in an animal model. Clinical and experimental emergency medicine, 7(2), 87-94. https://doi.org/10.15441/ceem.19.050
Weiss, Eric, et al. "Effect of complement C1-esterase inhibitor on brain edema and inflammation after mild traumatic brain injury in an animal model." Clinical and experimental emergency medicine vol. 7,2 (2020): 87-94. doi: https://doi.org/10.15441/ceem.19.050
Weiss E, Dhir T, Collett A, Reola M, Kaplan M, Minimo C, Omert L, Leung P. Effect of complement C1-esterase inhibitor on brain edema and inflammation after mild traumatic brain injury in an animal model. Clin Exp Emerg Med. 2020 Jun;7(2):87-94. doi: 10.15441/ceem.19.050. Epub 2020 Jun 30. PMID: 32635699; PMCID: PMC7348678.
Copy Download .nbib Format: NLM
Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential.

Frontiers in immunology

Sharp JA, Whitley PH, Cunnion KM, Krishna NK.
PMID: 25202312
Front Immunol. 2014 Aug 22;5:406. doi: 10.3389/fimmu.2014.00406. eCollection 2014.

The classical pathway of complement plays multiple physiological roles including modulating immunological effectors initiated by adaptive immune responses and an essential homeostatic role in the clearance of damaged self-antigens. However, dysregulated classical pathway activation is associated with antibody-initiated, inflammatory...

Cite
Sharp JA, Whitley PH, Cunnion KM, et al. Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Front Immunol. 2014;5:406doi: 10.3389/fimmu.2014.00406.
Sharp, J. A., Whitley, P. H., Cunnion, K. M., & Krishna, N. K. (2014). Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Frontiers in immunology, 5406. https://doi.org/10.3389/fimmu.2014.00406
Sharp, Julia A, et al. "Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential." Frontiers in immunology vol. 5 (2014): 406. doi: https://doi.org/10.3389/fimmu.2014.00406
Sharp JA, Whitley PH, Cunnion KM, Krishna NK. Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Front Immunol. 2014 Aug 22;5:406. doi: 10.3389/fimmu.2014.00406. eCollection 2014. PMID: 25202312; PMCID: PMC4141160.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries